CA2634006C - Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine - Google Patents

Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine Download PDF

Info

Publication number
CA2634006C
CA2634006C CA2634006A CA2634006A CA2634006C CA 2634006 C CA2634006 C CA 2634006C CA 2634006 A CA2634006 A CA 2634006A CA 2634006 A CA2634006 A CA 2634006A CA 2634006 C CA2634006 C CA 2634006C
Authority
CA
Canada
Prior art keywords
composition
liothyronine
stearic acid
ethylcellulose
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2634006A
Other languages
English (en)
French (fr)
Other versions
CA2634006A1 (en
Inventor
Alan Smith
Ann Margaret Dyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Archimedes Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Development Ltd filed Critical Archimedes Development Ltd
Publication of CA2634006A1 publication Critical patent/CA2634006A1/en
Application granted granted Critical
Publication of CA2634006C publication Critical patent/CA2634006C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2634006A 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine Expired - Fee Related CA2634006C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525461.0A GB0525461D0 (en) 2005-12-15 2005-12-15 Pharmaceutical compositions
GB0525461.0 2005-12-15
PCT/GB2006/004710 WO2007068948A2 (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising in particular thyroid hormones

Publications (2)

Publication Number Publication Date
CA2634006A1 CA2634006A1 (en) 2007-06-21
CA2634006C true CA2634006C (en) 2013-07-30

Family

ID=35736122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2634006A Expired - Fee Related CA2634006C (en) 2005-12-15 2006-12-15 Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine

Country Status (8)

Country Link
US (1) US8460702B2 (https=)
EP (1) EP1978950A2 (https=)
JP (1) JP2009519313A (https=)
BR (1) BRPI0619934A2 (https=)
CA (1) CA2634006C (https=)
GB (1) GB0525461D0 (https=)
IL (1) IL192091A (https=)
WO (1) WO2007068948A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
WO2013096596A1 (en) * 2011-12-20 2013-06-27 Latham Keith R Sustained drug release and improved product stability using non-covalent particle coating methods
EP3125873B1 (en) * 2014-04-04 2020-06-03 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules
DK3006045T3 (en) * 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US10695309B2 (en) 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
WO2020044314A1 (en) 2018-08-31 2020-03-05 Opko Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
US20220409567A1 (en) * 2021-06-23 2022-12-29 Thomas Winston Adjuvant and complementary therapies for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
DE69224809T2 (de) 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
GB9401892D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
EP1049459B1 (en) 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications
BR9914251A (pt) * 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6288117B1 (en) * 2000-03-23 2001-09-11 North Shore-Long Island Jewish Research Institute Method for treating congestive heart failure
CN1187052C (zh) 2000-03-30 2005-02-02 布里斯托尔-迈尔斯斯奎布公司 含有司他夫定(stavudine)的持续释放微球
EP1274401B2 (en) * 2000-04-10 2014-08-13 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
ITMI20022394A1 (it) * 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Also Published As

Publication number Publication date
CA2634006A1 (en) 2007-06-21
US20090130202A1 (en) 2009-05-21
JP2009519313A (ja) 2009-05-14
IL192091A0 (en) 2008-12-29
BRPI0619934A2 (pt) 2011-10-25
GB0525461D0 (en) 2006-01-25
WO2007068948A2 (en) 2007-06-21
EP1978950A2 (en) 2008-10-15
US8460702B2 (en) 2013-06-11
WO2007068948A3 (en) 2007-08-16
IL192091A (en) 2012-04-30

Similar Documents

Publication Publication Date Title
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
EP0533297B1 (en) Controlled-release pharmaceutical formulations
KR880001090B1 (ko) 디피리다몰의 경구용 제형의 제조방법
US6426091B1 (en) Sustained-release theophylline tablet
EP3054929B1 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
US4806361A (en) Medicaments in sustained release unit dose form
AU2015356781A1 (en) Gastroretentive extended release suspension compositions
EP4249055A2 (en) Tofacitinib oral sustained release dosage forms
JP2003528905A (ja) スタブジン含有持続放出性ビーズ剤
IL192091A (en) Sustained release pharmaceutical compositions comprising liothyronine, process for their preparation and their use in the manufacture of medicaments
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
WO1993000889A1 (en) METHOD FOR THE PREPARATION OF PROLONGED-RELEASE ORAL PHARMACEUTICAL FORMS CONTAINING ACTIVE SUBSTANCES HAVING A SOLUBILITY DEPENDENT UPON THE pH VALUE
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
WO2006130702A2 (en) Modified release formulations of antihypertensive drugs
AU2004251439A1 (en) Tablet comprising fluvastatin and carmellose calcium
EP3184101A1 (en) Levodopa and carbidopa modified release composition
WO2003043610A2 (en) A process for manufacture of a sustained release composition containing microbe
CZ2004235A3 (cs) Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice
WO2008062426A2 (en) Formulation of benzazepine derivatives
JPS6339814A (ja) トラニラストの経口用持続性製剤
Kumar Design, Development and Characterization of Verapamil Hydrochloride Pulsincap: In Vitro and In Vivo
MXPA01002821A (en) Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
HK1004887A1 (en) Controlled release flecainide acetate formulation
HK1004887B (en) Controlled release flecainide acetate formulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161215